Category Archives: Health

Global Laboratory Equipment Market Research Report (2018-2023)

Laboratory

Aarkstore Market Research Enterprise entitles the new approach into a Market Research Report “Global Laboratory Equipment Market (2018-2023)

The global laboratory equipment market is projected to expand at a compound annual growth rate (CAGR) of 8.0% during the 2018-2023 period, and will reach USD 84.4 Bn by 2023. Increasing life sciences research is responsible for a major part of the huge demand for laboratory equipment across the globe. The market is segmented based on technologies like spectroscopy, chromatography, flow cytometry, next-generation sequencing, etc. Increase in incidence of chronic diseases such as diabetes and respiratory ailments, and the higher demand for timely and early detection of diseases will aid the growth of the market in the near future.

Segmentation based on technologies

Based on technologies, the ‘other’ technologies segment had the highest market share (45.8%) in 2018, owing to a growing geriatric population, rapidly emerging diagnostics centers and hospitals, and technological advancements. Time-consuming operations and mechanical failure of equipment are major challenges faced by users. It is followed by the spectroscopy segment, with a market share of 21.3% in 2018. This is due to the increased demand for spectrometers in the life sciences sector for the analysis of drugs and biomolecules.

Regional insights

The North America laboratory equipment market is projected to expand at a CAGR of 7.8% during the 2018-2023 period, leading to global revenue of USD 33.7 Bn by 2023. An increasing number of clinical trials and higher funding for life sciences research will aid the growth of the market. Europe, a region characterized by high awareness and a wide range of laboratory equipment, is anticipated to expand at a CAGR of 7.9% during the forecast period. The Asia-Pacific laboratory equipment market is expected to expand at the highest CAGR (8.4%) during the 2018-2023 period. Latin America, and the Middle East and Africa markets, still in the nascent stages, will also experience high growth.

Companies covered
• Danaher Corporation
• Thermo Fischer
• Agilent Technologies
• Waters Corporation
• PerkinElmer Corporation
• Bio-Rad Laboratories
• Shimadzu Corporation
• Bruker Corporation

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Advertisements

Bio Pharmaceutical India Market Research Report

Bio-Pharmaceuticals Market

Aarkstore Market Research Enterprise entitles the new approach into a Market Research Report “Bio-Pharmaceuticals Market In India

Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. The biotechnology industry comprises bio-pharmaceuticals, bio-agriculture, bio-informatics, bio-services, and bio-industry.

Bio-pharmaceuticals Industry in India (2018-2023)

Market insights:
The bio-pharmaceuticals market in India is expected to reach a value of INR 2,891.70 Bn in FY 2023, expanding at a compound annual growth rate (CAGR) of ~31.7% since FY 2018. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications. Currently, bio-pharmaceuticals is one of the fastest growing biotechnology segments in India. The significant bio-pharmaceutical clusters of India are located in Haridwar, Sikkim, Hyderabad, Vishakhapatnam, Chennai, Pondicherry, Mysore, Mumbai, Ahmedabad, and Delhi NCR.

Government initiatives and investments:
The major investors in the Indian bio-pharmaceutical market are AstraZeneca, Johnson & Johnson, GlaxoSmithKline (GSK), Nipro and Otsuka. In 2017, 46 mergers and acquisition (M&A) deals were signed in the Indian bio-pharmaceutical market, generating business worth INR 94.77 Bn. The Indian government has taken the initiative to set up an electronic platform for regulating online pharmacies. ‘Pharma Vision 2020’ has been unveiled so that India can emerge as a global leader in terms of end-to-end drug manufacturing.

Key growth drivers of the market:
India comprises of ~0.13 Mn highly skilled and experienced scientists who serve as a strong support system for the business process of the bio-pharmaceutical industry. With the help of the educational qualifications and skillset of these people, India is considered to be a significant center for bio-pharmaceutical research and development (R&D), especially for vaccine manufacturing.
The Government of India has approved an investment of INR 15,000 Mn under the Innovate in India (i3) program, for collaboration of industrial organizations and academic organizations over the next five years. This program is considered to act as a significant action of the Government in its way of boosting bio-pharmaceutical production in the country.

Key deterrents to the growth of the market:

It often takes a long time for the manufacturing companies to launch a new market-ready bio-pharmaceutical product in India due to the existence of numerous regulatory challenges in the process.
Also, the Indian bio-pharmaceutical industry lacks proper infrastructure regarding limited government-sponsored laboratory space, consumables, chemical components, and equipment, which acts as a significant hindrance to the growth of the market.

Companies covered:
Biocon Ltd.
Cadila Healthcare Ltd.
Dr. Reddy’s Laboratories Ltd.
Panacea Biotec Ltd.
Wockhardt Ltd.
GSK Pharmaceuticals Ltd.
Bharat Biotech International Ltd.
Bharat Serums and Vaccines Ltd.
Indian Immunologicals Ltd.
Serum Institute of India Pvt. Ltd.


Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Global Mouthguard Market Status And Forecast Analysis 2016-2025

Mouthguard Market.jpg

Aarkstore Market Research culminates the newest Market Research Report “Global Mouthguard Market Status And Forecast Analysis 2016-2025

This report studies the Mouthguard market status and outlook of global and major regions, from angles of manufacturers, regions, product types and end industries; this report analyzes the top manufacturers in global and major regions, and splits the Mouthguard market by product type and applications/end industries.

The global Mouthguard market is valued at XX million USD in 2018 and is expected to reach XX million USD by the end of 2025.

The major players in global Mouthguard market includes:

ShockDoctor
ATI
Decathlon
Nike
Opro Mouthguards
Mueller
Venum
Battle Sports Science
Maxxmma
Fight Dentist
Mogo Sport

Major regions in global Mouthguard market includes:

Asia-Pacific
North America
Europe
South America
Middle East & Africa

Major types in global Mouthguard market includes:

Preformed Mouthguard
Thermoformed Mouthguard
Custom Mouthguard

Major application in global Mouthguard market includes:

Sport Enthusiasts
Player
Medical
For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

 

Dental consumables show marginal share growth.

Dental consumables are the devices consist of dental sundries used in dental clinics that assist in the treatment of patients. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market.

Global Dental Consumables Market 2023

Dental Consumables Report by Material, Application, and Geography-Global Forecast to 2023 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe, and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea, and China).

In this report, the global Dental Consumables market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2023, growing at a CAGR of XX% during the period 2019 to 2023.

The report firstly introduced the Dental Consumables basics: definitions, classifications, applications, and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, supply, demand, and market growth rate and forecast, etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include:

3M ESPE

Dentsply Sirona

Danaher

GC Corporation

Ivoclar Vivadent

Shofu

Mitsui Chemicals (Heraeus Kulzer)

VOCO GmbH

Ultradent

Coltene

DMG

The end users/applications and product categories analysis:

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

Amalgam

Composite Materials

Glass Ionomers

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Dental Consumables for each application, including-

Hospital

Dental Clinic

Category:  Healthcare Market Research Reports

Contact Details:

Aarkstore Enterprise

Phone: +91 998 729 5242 | contact@aarkstore.com

X-Ray Systems, on rising in medical fields

Medical Devices sector report, X-ray Systems – Medical Devices Pipeline Assessment, 2019 provides an overview of X-ray Systems currently in pipeline stage.

X-RAY SYSTEMS 2019

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in pipeline product development. It also provides information about clinical trials in progress, which includes the trial phase, trial status, trial start, and end dates, and, the number of trials for the key X-ray Systems pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

Scope

– Extensive coverage of the X-ray Systems under development

– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

– The report reviews the major players involved in the development of X-ray Systems and lists all their pipeline projects

– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

– The report provides key clinical trial data of ongoing trials specific to pipeline products

– Recent developments in the segment/industry.

Reasons to buy

The report enables you to –

– Formulate significant competitor information, analysis, and insights to improve R&D strategies

– Identify emerging players with the potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage

– Identify and understand important and diverse types of X-ray Systems under development

– Develop market-entry and market expansion strategies

– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

– In-depth analysis of the product’s current stage of development, territory and estimated launch date.

Category:  Healthcare Market Research Reports

Contact Details:

Aarkstore Enterprise

Phone: +91 998 729 5242 | contact@aarkstore.com

Full-Digital Ultrasonic Diagnostic Apparatus Industry Overview – Market Research Report 2019

Full-Digital Ultrasonic

Aarkstore Enterprise culminates the newest Market Research Report “Global Full-Digital Ultrasonic Diagnostic Apparatus”

Full-Digital Ultrasonic Diagnostic Apparatus Report by Material, Application, and Geography Global Forecast to 2023 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).

The report firstly introducedthe Full-Digital Ultrasonic Diagnostic Apparatus basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with:

1.) Basic Information;
2.) Asia Full-Digital Ultrasonic Diagnostic Apparatus Market;
3.) North American Full-Digital Ultrasonic Diagnostic Apparatus Market;
4.) European Full-Digital Ultrasonic Diagnostic Apparatus Market;
5.) Market Entry and Investment Feasibility;
6.) Report Conclusion.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Global Multiscan Ultrasonic Diagnostic Equipment Market Research Report 2017

Asia Pacific Clinical Diagnostics Assays Market Report (2014-2024) – Market Size, Share, Price, Trend and Forecast

North America Clinical Diagnostics Assays Market Report (2014-2024) – Market Size, Share, Price, Trend and Forecast

Global Clinical Diagnostics Assays Market Report 2019 – Market Size, Share, Price, Trend and Forecast

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

Market for CAR-T Cell Therapy

Cell Therapy

Aarkstore Enterprise culminates the newest Market Research Report “Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy.

In 2017, the world witnessed a historic CAR-T cell therapy approval when on August 30, 2017, Tisagenlecleucel (Kymriah) was approved by U.S. FDA for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). On May 1, 2018, FDA approved Kymriah for a second indication (diffuse large B-cell lymphoma). By October 18, 2017, the FDA granted approval for Yescarta for treating patients with relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL) and other rare large B-cell lymphomas. Other notable approvals for CAR-T cell therapy products have also been achieved.

In August 2018, Kymriah and Yescarta secured approval in Europe, indicating the willingness of European regulators to usher in a new age of regenerative medicine. Novartis’ Kymriah was given marketing authorization in the EU for the treatment of blood cancers, including B-cell acute lymphoblastic leukaemia (ALL) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Gilead/Kite Pharma’s Yescarta was authorized as a treatment for adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL). Health Canada approved Kymriah as the first CAR-T therapy in Canada and the Therapeutic Goods Administration (TGA) approved it as the first CAR-T therapy in Australia.

What is CAR-T Cell Therapy?

Chimeric antigen receptors (CARs) are genetically engineered cells that are developed in the laboratory and infused into a patient to help in detecting and fighting cancer. The protein constructs stimulate anti-cancer T-cells, which in turn boost a patient’s immune system. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
CAR-T is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”

How Does CAR-T Cell Therapy Work?

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Like all cancer therapies, CAR-T cell therapy can also cause a number of side effects. However, all these side effects can be managed with standard supportive therapies including steroids. The widespread research activities, worldwide clinical trials and treatments in a limited number of U.S. hospitals have created a robust CAR T-cell market. This billion dollar market and projected growth would have been not possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers.

Market for CAR-T Cell Therapy

CAR-T cell therapy has swept the biotech industry by storm in recent years, creating hope that it could welcome in a new age of cancer treatment. However, the remarkable success stories have come from targeting CD19, which is now considered an antigen that holds the key to a limited range of blood cancers. Presently, this hematological arena is a highly competitive therapy space that is being shared between among leading CAR-T companies.

Scientists, investors and developers invariably agree that the key to longer-term success in this space depends on solving two major problems: identifying antigens other than CD19 that can be targeted with CAR-T therapy with strong efficacy and going beyond liquid cancers into solid tumor indications. CAR-T cell products to deal with solid tumors will undoubtedly offer a larger market potential.

However, it is not an easy task to identify the antigens found on the cells of solid tumors. There are reasons why CD19 is the most common target. It is seen solely on B cells, whose destruction via CAR-T therapy offers a straightforward route for treating B-cell leukemias and lymphomas. At the same time, loss of the body’s B cells is not particularly problematical, because their antibody-producing function can be reinstated by injecting intravenous immunoglobulin (IVIG) to patients.

Currently, the only two non-CD19-directed CAR-T therapies are those that target CD22 in B-cell malignancies and B-cell maturation antigen (BCMA) in multiple myeloma. CD22 is structurally analogous to CD19, while BCMA is an antigen expressed on plasma cells, whose functional loss can also be replaced with IVIG.

The problem with solid tumors is that there is little evidence of CAR-T being able to overcome the numerous difficulties that exist for these to be targeted efficiently. However, both academic and commercial groups are racing against time to identify the antigens on solid tumor cells and develop suitable CAR-T cells, because it represents large market potential.
There are several reasons which make solid tumors difficult to treat using CAR-T cell therapies. Globally, solid tumors outnumber the hematological tumors by 10 to one. In 2015, Novartis and PENN reported that their CART-meso failed to show any effect in patients with mesothelioma, ovarian cancer and pancreatic cancer. Moreover, there was very poor persistence of CAR-T cells in the patients.

The difficulty with solid tumors is that they are usually surrounded by a hostile, immuno-suppressive microenvironment. This environment presents many inhibitory factors that prevent CAR-T cells from reaching them. A typical CAR-T approach will not have success under these conditions. For this reason, Juno and Novartis are engaging in constructing CAR-T cells with novel designs that incorporate additional elements to boost activity within this setting. Currently, these products are in preclinical development.

Driving Forces for the CAR-T Therapy Market

With growing demand for CAR-T therapies, CAR-T companies are proliferating. Growing numbers of these companies are supported by:
• Increasing investment flowing into CAR-T cell research
• Landmark approvals of CAR-T cell therapies by the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA)
• Major acquisitions within the CAR-T industry
• Large IPOs within the CAR-T industry

As mentioned, 2017 was the first year that the U.S. FDA approved a CAR-T cell therapy, approving Kymriah in August 2017 and Yescarta in October 2017. Novartis produced Kymriah, a CAR-T therapy used to treat leukemia, while Gilead/Kite Pharma developed Yescarta, a CAR-T therapy for patients with lymphomas. Approvals for these products are now spreading globally, with authorizations permitted by the EU, Canada, and Australia, among others. The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, both from regulators, as well as from the broader scientific and medical communities.
CAR-T funding is also on the rise. At first the trend was subtle, but the tide swelled as CAR-T therapies like Kymriah and Yescarta reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. Following IPOs by CAR-T players Kite Pharma, Bellicum, Juno Therapeutis and Cellectis totaling over $750 million, CAR-T developer Autolus announced a $150 million IPO.
This has bought the total value of recent CAR-T initial public offerings (IPO’s) to nearly $1 billion.

CAR-T Industry Deal-Making

The CAR-T industry has also witnessed aggressive deal-making in recent years. Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017. After $20 billion of market capitalization from the CAR-T companies in 2018, the CAR-T market has continued to gain momentum.
There have also been more than a dozen CAR-T deals between pharmaceutical companies and academic institutions, with the best known being the partnership between Novartis and the University of Pennsylvania (UPenn). When Kymriah™ because the first CAR-T cell therapy to be approved in the U.S. in August 2017, it resulted from a 5-year collaboration between UPenn and Novartis.

CAR-T financing rounds have also proliferated. In one major example, Celularity raised $250 million in February 2018 to support development of placental-derived products, including T-cells that will be immune advantaged because of their derivation from the placenta. Celularity is looking to burst a major bottleneck in the industry by deriving T-cells from a single (allogeneic) cell line, potentially positioning itself to slash the price point for CAR-T treatments. In other significant example, London-based CAR-T start-up Allogene Therapeutics entered into an asset contribution deal with Pfizer in April 2018, as well as announced a $300 million Series A round.

To better understand and compete within the rapidly expanding CAR-T marketplace, claim this global strategic report to learn the identities and strategies of leading market competitors, access market size data accompanied by market segmentation and forecasts, review clinical trial activity within the sector, assess CAR-T market approvals by region, and importantly, evaluate industry deal-making, emerging technologies, and future directions for the industry at large.

For more inquiry contact our sales team at contact@aarkstore.com

Related Reports:

Contact Details:

Aarkstore Enterprise
Phone: +91 – 22 2756 4963
24/7 Online Support: +91 9987295242
Email: enquiry@aarkstore.com
Our website: https://www.aarkstore.com
Our blog: https://www.aarkstore.com/blog
Follow us on LinkedIn – https://www.linkedin.com/company/aarkstore-enterprise/

%d bloggers like this: